Video

Combination neoadjuvant nivolumab/gemcitabine-cisplatin is efficacious in pathologically downstaging MIBC

Author(s):

Urology Times staff

“The complete response rates were 49%, which is quite impressive compared to historical controls,” says Shilpa Gupta, MD.

In this video, Shilpa Gupta, MD, discusses the background and findings of the study, “Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Gupta is the director of genitourinary oncology at Cleveland Clinic in Ohio.

Related Videos
Timothy Lyon, MD, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
1 expert is featured in this series.
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
1 expert is featured in this series.
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
Related Content
UGN-101 offers durable RFS in low-grade upper tract urothelial carcinoma
January 22nd 2025

UGN-101 offers durable RFS in low-grade upper tract urothelial carcinoma

Hannah Clarke
"The three-year durability data from this study further validate the potential of JELMYTO in providing long-term disease control for patients with low-grade upper tract urothelial cancer,” says Solomon L. Woldu, MD.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Challenges in plasmacytoid urothelial carcinoma underscore need for novel treatment options
January 17th 2025

Challenges in plasmacytoid urothelial carcinoma underscore need for novel treatment options

Fed Ghali, MD
“If patients are not experiencing a clear clinical benefit for chemotherapy prior to surgery, we need to be really thoughtful about how we use it,” says Fed Ghali, MD.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
New Drug Application initiated with FDA for TAR-200 for NMIBC
January 15th 2025

New Drug Application initiated with FDA for TAR-200 for NMIBC

Hannah Clarke Benjamin P. Saylor Kyle Doherty
The NDA is supported by data from cohort 2 of the phase 2b SunRISe-1 trial.
Bladder tumor-focused adaptive radiotherapy shows feasibility in phase 2 trial
January 14th 2025

Bladder tumor-focused adaptive radiotherapy shows feasibility in phase 2 trial

Hannah Clarke
“In this phase 2 study, an image-guided adaptive strategy enabled radiotherapy dose escalation to over 86% of patients’ bladder tumors without significant increase in toxicity,” wrote the authors.
© 2025 MJH Life Sciences

All rights reserved.